Abstract: Objective：To discuss the clinical and pathological features, treatment and prognosis of small cell neuroendocrine carcinoma of the cervix (SCNECC). Methods：From June 2012 to September 2017, 19 cases of SCNECC patients were reviewed and their data were analyzed retrospectively. Results：Patients′ age ranged from 30-63 years, with average of （45.8±10.0） years. Clinical stage: 7 stageⅠB1, 5 stageⅠB2, 2 stageⅡA1, 4 stageⅡB, 1 stageⅢB. The tumor size was 2-10 cm, with the average of (4.29±2.43) cm. 16 cases were positive for HPV 18, and 1 case was positive for HPV16. 17 patients underwent radical surgery followed by adjuvant chemotherapy, including 8 patients were treated by neoadjuvant chemotherapy, 9 patients received radiotherapy. Two patients who didn′t received surgery were treated by chemoradiotherapy. The disease-free 1-, 2-, and 5-year survival rates were 58.6%, 50.2%, 12.6% respectively. The overall 1-, 2-, and 5-year survival rates were 72.8%, 54.6%, 27.3%, respectively. Univariate analysis showed that clinical stage (＞ⅡA), lymph node metastasis and the tumor size (＞4 cm) were the prognostic risk factors. Conclusions：Small cell neuroendocrine carcinoma of the cervix is a rare disease and associated with high mortality. The diagnosis relys on pathology. Radical surgery is the major therapy for early-stage patients, adjuvant chemotherapy has important significance.

Key words: Uterine cervical neoplasms, Small cell neuroendocrine carcinoma, Carcinoma, neuroendocrine, Therapy, Prognosis, Case reports